Shares of USA-based was Xeris Biopharma (Nasdaq: XERS) were up 12% to $2.67 in morning trading yesterday, after it announced a licensing deal with biotech major Amgen (Nasdaq: AMGN). The shares have more than doubled in the last year.
Xeris has granted an exclusive worldwide license for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect technology in thyroid eye disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease.
Teprotumumab-trbw, known as Tepezza in the USA, was developed and marketed Horizon Therapeutics, the $27.8 billion acquisition of which Amgen completed last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze